Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The palmitoylation/depalmitoylation cycle of posttranslational processing is a potential therapeutic target for selectively inhibiting the growth of hematologic cancers with somatic NRAS mutations. To investigate this question at the single-cell level, we constructed murine stem cell virus vectors and assayed the growth of myeloid progenitors. Whereas cells expressing oncogenic N-RasG12D formed cytokine-independent colonies and were hypersensitive to GM-CSF, mutations within the N-Ras hypervariable region induced N-Ras mislocalization and attenuated aberrant progenitor growth. Exposing transduced hematopoietic cells and bone marrow from Nras and Kras mutant mice to the acyl protein thioesterase inhibitor palmostatin B had similar effects on protein localization and colony growth. Importantly, palmostatin B-mediated inhibition was selective for Nras mutant cells, and we mapped this activity to the hypervariable region. These data support the clinical development of depalmitoylation inhibitors as a novel class of rational therapeutics in hematologic malignancies with NRAS mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
Self-citationRas oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467
Germline KRAS mutations cause Noonan syndrome
Schubbert, S., Zenker, M., Rowe, S. L., Böll, S., Klein, C., Bollag, G., van der Burgt, I., Musante, L., Kalscheuer, V., Wehner, L.-E., et al. (2006) · Nature Genetics · doi:10.1038/ng1748 · Cited by 730
Self-citationBraun, B. S., Tuveson, D. A., Kong, N., Le, D. T., Kogan, S. C., Rozmus, J., Le Beau, M. M., Jacks, T. E., & Shannon, K. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307203101 · Cited by 299
Self-citation
Cited by
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795
Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy
Huber, K. V. M., Salah, E., Radic, B., Gridling, M., Elkins, J. M., Stukalov, A., Jemth, A.-S., Göktürk, C., Sanjiv, K., Strömberg, K., et al. (2014) · Nature · doi:10.1038/nature13194 · Cited by 395
Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Cox, A. D., Der, C. J., & Philips, M. R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3214 · Cited by 351
Protein acylation: mechanisms, biological functions and therapeutic targets
Shang, S., Liu, J., & Hua, F. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01245-y · Cited by 235
“Palmostatin B (PB) and palmostatin M (PM) are APT inhibitors that covalently modify and inactivate the serine residue in the active site but lack specificity between APT1 and APT2.(384,385) PB treatment was found to block the proliferation of AML blasts from a mouse model that harbored oncogenic N-Ras.”
BackgroundInfluentialTargeting oncogenic Ras signaling in hematologic malignancies
Ward, A. F., Braun, B. S., & Shannon, K. M. (2012) · Blood · doi:10.1182/blood-2012-05-378596 · Cited by 209
Self-citation
Metadata
- Authors
- Xu, J., Hedberg, C., Dekker, F. J., Li, Q., Haigis, K. M., Hwang, E., Waldmann, H., & Shannon, K.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2012-01-26
- Volume
- 119
- Issue
- 4
- Pages
- 1032-1035
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1994491427
- Cited by
- 80
- References
- 4
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras. https://app.cochat.ai/papers/10.1182/blood-2011-06-358960
- The paper
- Xu, J., Hedberg, C., Dekker, F. J., Li, Q., Haigis, K. M., Hwang, E., Waldmann, H., & Shannon, K. (2012). Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras. Blood. https://doi.org/10.1182/blood-2011-06-358960
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.